Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1012 in Locally Advanced or Metastatic Solid Tumors
NCT06171178Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- May 2024
- Primary completion
- Sep 2025
- Modality
- Oncolytic Viruses, Immunotoxins
- Countries
- 1
01
Overview
Phase 1, open-label trial of Oncolytic vaccinia virus expressing leptin/IL-2 fusion protein ASP1012 in solid tumor, melanoma, gastric cancer (GC) and 2 more (8 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 19 months and 4 more. Started May 2024; status: terminated.
02
Drugs
Oncolytic vaccinia virus expressing leptin/IL-2 fusion protein ASP1012
03
Conditions
solid tumormelanomagastric cancer (GC)colorectal cancer (CRC)ovarian cancer
Beyond the preview
Go deeper on NCT06171178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171178.